Related Experiment Video

Updated: Mar 14, 2026

Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells
09:32

Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells

Published on: February 8, 2018

15.7K

Resistance patterns to anti-PD-1 therapy in metastatic melanoma

Alpaslan Ozgun1, Vernon K Sondak1, Joseph Markowitz2

  • 1Department of Cutaneous Oncology, Moffitt Cancer Center, and Department of Oncologic Sciences, University of South Florida Morsani College of Medicine, Tampa, FL, USA.

Chinese Clinical Oncology
|October 6, 2016
PubMed
Abstract

No abstract available in PubMed .

More Related Videos

Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood
06:07

Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood

Published on: February 5, 2020

6.2K
A 3D Organotypic Melanoma Spheroid Skin Model
08:49

A 3D Organotypic Melanoma Spheroid Skin Model

Published on: May 18, 2018

16.7K

Related Experiment Videos

Last Updated: Mar 14, 2026

Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells
09:32

Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells

Published on: February 8, 2018

15.7K
Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood
06:07

Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood

Published on: February 5, 2020

6.2K
A 3D Organotypic Melanoma Spheroid Skin Model
08:49

A 3D Organotypic Melanoma Spheroid Skin Model

Published on: May 18, 2018

16.7K

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.9K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.9K
Skin Cancer01:30

Skin Cancer

6.5K
Skin cancer is a type of cancer that occurs when there is an abnormal growth of skin cells, usually triggered by damage to the DNA within the skin cells. It is primarily caused by exposure to ultraviolet (UV) radiation from the sun or artificial sources like tanning beds. Skin cancer is the most common type of cancer worldwide, and its incidence continues to rise.
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
6.5K

Articles linked to this work by shared authors, journal, and citation graph.

pAc/Emm55 increases anti-melanoma immunity via TLR2 signaling in dendritic cells and improves checkpoint blockade efficacy.

Frontiers in immunology·2026

Evidence of genetic susceptibility to immune-related dermatitis in patients with melanoma treated with immune checkpoint inhibitors.

Melanoma research·2026

Immunologic determinants of infusion products and the tumor microenvironment govern response to TIL therapy in advanced melanoma.

Med (New York, N.Y.)·2026

iNOS is a key mediator of anti-PD-1 melanoma therapy response.

Frontiers in immunology·2026

Addressing Biases in Analysis of Time of Infusion: NCI/SWOG Trial S1404 Among Participants With High-Risk Resectable Melanoma Who Received Adjuvant Anti-PD-1 Therapy.

JCO oncology practice·2026

Predicting immune-related thyroiditis using polygenic risk scores in patients with advanced melanoma.

Journal for immunotherapy of cancer·2026

Preliminary study on efficacy and safety of pixantrone in relapsed/refractory aggressive B-cell lymphomas: multicenter, retrospective cohort study by Polish Lymphoma Research Group (PLRG).

Chinese clinical oncology·2026

Efficacy and safety of TAS-102 followed by regorafenib or reverse sequence in later-line treatment of metastatic colorectal cancer: a systematic review and meta-analysis.

Chinese clinical oncology·2026

Network pharmacology of Sijunzi decoction in pancreatic cancer.

Chinese clinical oncology·2026

Drug-induced liver injury and acute pancreatitis during trastuzumab therapy in a BRCA1-mutated, HER2-positive breast cancer patient: a case report.

Chinese clinical oncology·2026

Epidemiology, diagnosis, and treatment of primary pulmonary mucosa-associated lymphoid tissue lymphoma.

Chinese clinical oncology·2026

Biliary neuroendocrine tumors: a narrative review of current diagnostics and management strategies.

Chinese clinical oncology·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us